Delivery Order SPE2DB22D1202-SPE2DB25FVGM0
- Not listed
- The Defense Logistics Agency awarded a $1,505.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a delivery order valued at $1,403.84 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical supply transaction executed without set-aside provisions. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $1,317.48 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order with no set-aside designation, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,516.44 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on August 5, 2025, with completion scheduled for August 6, 2025. The contract employs firm fixed price pricing with no small business set-aside and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,227.36 to supply Lantus SoloStar 100 Unit/ML 3ML insulin pens. This non-competitive, firm fixed price delivery order was issued on July 30, 2025, with an ultimate completion date of July 31, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The U.S. Defense Department's Medical Supply Chain awarded a $1,694.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens on July 31, 2025, with an ultimate completion date of August 1, 2025. The contract was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $6,703.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside contract represents a single delivery order for pharmaceutical supplies to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $3,049.07 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This firm fixed price contract, with an ultimate completion date of July 24, 2025, represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was competitively awarded with no set-aside designation, with performance to be executed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $1,379.08 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens (3mL format) on August 5, 2025, with completion scheduled for August 6, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a small-value pharmaceutical procurement supporting military and federal healthcare operations. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGM0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,045.60 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and is performed at the contractor's Conshohocken, Pennsylvania location. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle valued through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that fulfills critical federal medical procurement needs across the Department of Defense healthcare system, including support to the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal contract awards demonstrates significant capability in delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This contract for insulin delivery reflects the company's ongoing role as a key vendor supporting military personnel and veteran healthcare through the DLA's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 8/5/25 |